Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Nov:32:36-41.
doi: 10.1016/j.parkreldis.2016.08.010. Epub 2016 Aug 12.

Medium-term prognosis of an incident cohort of parkinsonian patients compared to controls

S Fielding  1 , A D Macleod  1 , C E Counsell  2
Affiliations

Medium-term prognosis of an incident cohort of parkinsonian patients compared to controls

S Fielding et al. Parkinsonism Relat Disord. 2016 Nov.

Abstract

Background: The best data on prognosis comes from population-based incident cohorts but few such cohorts exist for Parkinson's disease and atypical parkinsonism.

Methods: The PINE study is a prospective follow-up study of an incident cohort of people with degenerative or vascular parkinsonism and age-sex matched controls. Participants have annual follow-up from diagnosis until death with review of primary/secondary care records and linkage to the UK death register. Data are collected on survival, disability (dependency on others for activities of daily living) and institutionalization. Research criteria are used to guide the clinical diagnosis, which is updated annually. We compared all-cause mortality, disability and institutionalization in patients (subdivided by diagnosis) and controls, adjusted for important confounders.

Results: 323 incident parkinsonian patients (199 Parkinson's disease, 124 atypical parkinsonism, mean age at diagnosis 75yrs) and 262 controls (mean age 75yrs) had 1349 and 1334 person-years follow-up respectively (maximum follow-up 10 years). All outcomes were worse in parkinsonian patients than controls, especially in atypical parkinsonism (adjusted mortality hazards ratios Parkinson's disease 2.49, 95%CI 1.72-3.58, atypical parkinsonism, 6.85, 95%CI 4.78-9.81). Median survival times for Parkinson's disease and atypical parkinsonism were 7.8 and 2.7 years respectively but were very age-dependent. At three years the rates of death or dependency were controls 21%, Parkinson's disease 46%, atypical parkinsonism 96% whilst overall institutionalization rates were 5%, 15% and 55% respectively.

Conclusion: The prognosis of Parkinson's disease and atypical parkinsonism in this unselected incident cohort was significantly worse than previously reported. This has important implications for patient management.

Keywords: Cohort study; Parkinson's disease; Parkinsonian disorders; Prognosis; Survival.

PubMed Disclaimer

Figures

Fig. S1
Fig. e1: Study flow diagram.
Fig. S2
Fig. e2: Kaplan-Meier curves for all-cause mortality in Parkinson's disease by age at diagnosis.
Fig. S3
Fig. e3: Kaplan-Meier curves for time to all-cause mortality by individual diagnostic category.
Fig. S4
Fig. e4: Cumulative incidence curves for institutionalization by individual diagnostic category.
Fig. 1
Fig. 1
Kaplan-Meier curves for all-cause mortality by grouped diagnostic category.
Fig. 2
Fig. 2
Cumulative incidence curves for institutionalization by grouped diagnostic category.
See this image and copyright information in PMC

References

    1. Hemingway H., Croft H.P., Perel P., Hayden J.A., Abrams K., Timmis A., Briggs A., Udumyan R., Moons K.G., Steyerberg E.W., Roberts I., Schroter S., Altman D.G., Riley R.D. PROGESS group, Prognosis research strategy (PROGRESS) 1: a framework for researching clinical outcomes. Br. Med. J. 2013;346:e5595. - PMC - PubMed
    1. Lindgren P., von Campenhausen S., Spottke E., Siebert U., Dodel R. Cost of Parkinson's disease in europe. Eur. J. Neurol. 2005;12(Suppl 1):68–73. - PubMed
    1. Laupacis A., Wells G., Richardson W.S., Tugwell P. Users' guides to the medical literature. V. How to use an article about prognosis. JAMA. 1994;272:234–237. - PubMed
    1. Williams-Gray C.H., Mason S.L., Evans J.R., Foltynie T., Brayne C., Robbins T.W., Barker R.A. The CamPaIGN study of Parkinson's disease: 10 year outlook in an incident population-based cohort. J. Neurol. Neurosurg. Psychiatry. 2013;84:1258–1264. - PubMed
    1. Macleod A.D., Taylor K.S.M., Counsell C.E. Mortality in Parkinson's disease: a systematic review and meta-analysis. Mov. Disord. 2014;29:1615–1622. - PubMed

Publication types

LinkOut - more resources